Search

Your search keyword '"Tufman, Amanda"' showing total 571 results
Start Over Author "Tufman, Amanda"
571 results on '"Tufman, Amanda"'

5. Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations

Author

Kron, Anna, Scheffler, Matthias, Wiesweg, Marcel, Hummel, Horst-Dieter, Kulhavy, Jonas, Gatteloehner, Stefan, Kollmeier, Jens, Schubart, Christoph, Groß, Thorben, Demes, Melanie-Christin, Keymel, Stefanie, Joosten, Maria, Merkelbach-Bruse, Sabine, Wölwer, Christina Bianca, Tufman, Amanda, Kauffmann-Guerrero, Diego, Oeser, Katharina, Zehaczek, Melanie, Jeratsch, Ulli, and Wolf, Juergen

Published
2024
Full Text
View/download PDF

6.  Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study

Author

Käsmann, Lukas, Eze, Chukwuka, Taugner, Julian, Nieto, Alexander, Hofstetter, Kerstin, Kröninger, Sophie, Guggenberger, Julian, Kenndoff, Saskia, Flörsch, Benedikt, Tufman, Amanda, Reinmuth, Niels, Duell, Thomas, Belka, Claus, and Manapov, Farkhad

Published
2023
Full Text
View/download PDF

8. Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Author

Ababei, Juliana, Alt, Jürgen, Ammon, Andreas, Anhuf, Jürgen, Azeh, Ivo, Bauer, Stefan, Behringer, Dirk, Berger, Winfried, Bernhardt, Christiane, Bertram, Mathias, Boesche, Michael, Bohnet, Sabine, Bruch, Harald-Robert, Brückl, Wolfgang, Burkhard-Meier, Ulrike, Christopoulos, Petros, Däßler, Klaus-Ulrich, de Wit, Maike, Dechow, Tobias, Depenbusch, Reinhard, Dietze, Lutz, Dommach, Markus, Dörfel, Steffen, Eberhardt, Wilfried, Elender, Corinna, Elsel, Wolfgang, Emde, Till-Oliver, Faehling, Martin, Fietz, Thomas, Fischer, Jürgen R., Flieger, Dimitri, Freidt, Anke, Freier, Werner, Frenzel, Christian, Fuchs, Florian, Fuchs, Roswitha, Gaska, Tobias, Gleiber, Wolfgang, Grah, Christian, Griesinger, Frank, Grohé, Christian, Groschek, Matthias, Güldenzoph, Björn, Günther, Andreas, Haas, Siegfried, Hackenthal, Matthias, Hagen, Volker, Hahn, Lars, Hannig Carla, Verena, Hansen, Richard, Harich, Hanns-Detlev, Heilmann, Monika, Heinrich, Kathrin, Hering-Schubert, Christiane, Heßling, Jörg, Hoffknecht, Petra, Hortig, Patricia, Hübner, Gerdt, Hummel, Horst-Dieter, Hutzschenreuter, Ulrich, Illmer, Thomas, Innig, Georg, Jaeschke, Bastian, Junghanß, Christian, Kaiser, Ulrich, Kamal, Haytham, Kambartel, Kato, Kern, Jens, Kimmich, Martin, Kingreen, Dorothea, Kirchen, Heinz, Klausmann, Martine, Klein, Ortwin, Kokowski, Konrad, Körber, Wolfgang, Kortsik, Cornelius, Koschel, Dirk, Krämer, Benoit, Krammer-Steiner, Beate, Laack, Eckart, Lamberti, Christof, Leistner, Rumo David, Losem, Christoph, Lück, Andreas, Maintz, Christoph, Martin, Kerstin, Medgenberg, Dirk, Metzenmacher, Martin, Meyer zum Büschenfelde, Christian, Meyn, Philipp, Moorahrend, Enno, Müller, Annette, Müller, Lothar, Neise, Michael, Nückel, Holger, Nusch, Arnd, Overbeck, Tobias, Pelz, Henning, Petersen, Volker, Peuser, Bettina, Plath, Margarete, Randerath, Winfried J., Rauh, Jacqueline, Reck, Martin, Reichert, Dietmar, Reinmuth, Niels, Reiser, Marcel, Repp, Roland, Reschke, Daniel, Rittmeyer, Achim, Rodemer, Yolanda, Sackmann, Sandra, Sadjadian, Parvis, Sandner, Reiner, Sauer, Annette, Schäfer, Harald, Schaudt, Christoph, Schlag, Rudolf, Schmidt, Burkhard, Schmitz, Stephan, Schröder, Jan, Schroeder, Michael, Schulze, Mathias, Schumann, Christian, Schütte, Wolfgang, Schwaiblmair, Martin, Schwindt Peter, Florian, Sebastian, Martin, Seese, Bernd, Seipelt, Gernot, Sorgenfrei, Thomas, Steiff, Johannes, Steiniger, Heike, Trarbach, Tanja, Tufman, Amanda, Uhlig, Jens, Vehling-Kaiser, Ursula, von der Heyde, Eyck, von Verschuer, Ulla, Waller, Cornelius, Wehler, Thomas, Weißenborn, Georg, Weißinger, Florian, Wermke, Martin, Wesseler, Claas, Wiegand, Jörg, Wilhelm, Stefan, Wilke, Jochen, Zahn, Mark-Oliver, Zaiss, Matthias, Zeth, Matthias, Eberhardt, Wilfried E.E., Brueckl, Wolfgang M., Jänicke, Martina, Fleitz, Annette, Zacharias, Stefan, Hipper, Annette, Groth, Annika, Weichert, Wilko, and Thomas, Michael

Published
2024
Full Text
View/download PDF

11. Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board

Author

Heinrich, Kathrin, Miller-Phillips, Lisa, Ziemann, Frank, Hasselmann, Korbinian, Rühlmann, Katharina, Flach, Madeleine, Biro, Dorottya, von Bergwelt-Baildon, Michael, Holch, Julian, Herold, Tobias, von Baumgarten, Louisa, Greif, Philipp A., Jeremias, Irmela, Wuerstlein, Rachel, Casuscelli, Jozefina, Spitzweg, Christine, Seidensticker, Max, Renz, Bernhard, Corradini, Stefanie, Baumeister, Philipp, Goni, Elisabetta, Tufman, Amanda, Jung, Andreas, Kumbrink, Jörg, Kirchner, Thomas, Klauschen, Frederick, Metzeler, Klaus H., Heinemann, Volker, and Westphalen, C. Benedikt

Published
2023
Full Text
View/download PDF

12. First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations

Author

Blasi, Miriam, Kuon, Jonas, Lüders, Heike, Misch, Daniel, Kauffmann-Guerrero, Diego, Hilbrandt, Moritz, Kazdal, Daniel, Falkenstern-Ge, Roger-Fei, Hackanson, Björn, Dintner, Sebastian, Faehling, Martin, Kirchner, Martina, Volckmar, Anna-Lena, Kopp, Hans-Georg, Allgäuer, Michael, Grohé, Christian, Tufman, Amanda, Reck, Martin, Frost, Nikolaj, Stenzinger, Albrecht, Thomas, Michael, and Christopoulos, Petros

Published
2024
Full Text
View/download PDF

13. Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment

Author

Holzgreve, Adrien, Taugner, Julian, Käsmann, Lukas, Müller, Philipp, Tufman, Amanda, Reinmuth, Niels, Li, Minglun, Winkelmann, Michael, Unterrainer, Lena M., Nieto, Alexander E., Bartenstein, Peter, Kunz, Wolfgang G., Ricke, Jens, Belka, Claus, Eze, Chukwuka, Unterrainer, Marcus, and Manapov, Farkhad

Published
2023
Full Text
View/download PDF

14. Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer

Author

Taugner, Julian, Eze, Chukwuka, Käsmann, Lukas, Roengvoraphoj, Olarn, Gennen, Kathrin, Karin, Monika, Petrukhnov, Oleg, Tufman, Amanda, Belka, Claus, and Manapov, Farkhad

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Lung Cancer, Lung, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.4 Surgery, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Chemoradiotherapy, Disease-Free Survival, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Retrospective Studies, Salvage Therapy, Treatment Outcome, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

BackgroundLoco-regional and distant failure are common in inoperable stage III non small-cell lung cancer (NSCLC) after chemoradiotherapy (CRT). However, there is limited real-world data on failure pattern, patient prognosis and salvage options.MethodsWe analysed 99 consecutive patients with inoperable stage III NSCLC treated with CRT between 2011 and 2016. Follow up CT scans from date of the first-site failure were matched with the delivered radiation treatment plans. Intra-thoracic loco-regional relapse was defined as in-field (IFR) vs. out-of-field recurrence (OFR) [in- vs. outside 50Gy isodose line in the involved lung], respectively. Extracranial distant (DMs) and brain metastases (BMs) as first site of recurrence were also evaluated. Using the Kaplan-Meier method, impact of salvage surgery (sS), radiotherapy (sRT), chemotherapy (sCT) and immunotherapy (sIO) on patient survival was assessed.ResultsMedian follow-up was 60.0 months. Median PFS from the end of CRT for the entire cohort was 7.5 (95% CI: 6.0-9.0 months) months. Twenty-six (26%) and 25 (25%) patients developed IFR and OFR. Median time to diagnosis of IFR and OFR was 7.2 and 6.2 months. In the entire cohort, onset of IFR and OFR did not influence patient outcome. However, in 73 (74%) patients who survived longer than 12 months after initial diagnosis, IFR was a significant negative prognostic factor with a median survival of 19.3 vs 40.0 months (p

Published
2020

15. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

Author

Gennen, Kathrin, Käsmann, Lukas, Taugner, Julian, Eze, Chukwuka, Karin, Monika, Roengvoraphoj, Olarn, Neumann, Jens, Tufman, Amanda, Orth, Michael, Reu, Simone, Belka, Claus, and Manapov, Farkhad

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Lung Cancer, Cancer, Clinical Research, Lung, Aged, B7-H1 Antigen, CD8-Positive T-Lymphocytes, Carcinoma, Non-Small-Cell Lung, Chemoradiotherapy, Female, Humans, Lung Neoplasms, Lymphocytes, Tumor-Infiltrating, Male, Middle Aged, Prognosis, Retrospective Studies, Tumor Microenvironment, TILs, PDL1, Prognostic factors, Checkpoint inhibition, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

BACKGROUND/AIM:mmune checkpoint inhibition (CPI) has an increasing impact in the multimodal treatment of locally advanced non-small cell lung cancer (LA-NSCLC). Increasing evidence suggests treatment outcome depending on tumor cell PD-L1 expression. The purpose of this retrospective study was to investigate the prognostic value of PD-L1 expression on tumor cells in combination with CD8+ tumor stroma-infiltrating lymphocyte (TIL) density in inoperable LA-NSCLC treated with concurrent chemoradiotherapy (CRT). PATIENTS AND METHOD:We retrospectively assessed clinical characteristics and initial tumor biopsy samples of 31 inoperable LA-NSCLC patients treated with concurrent CRT. Prognostic impact of tumor cell PD-L1 expression (0% versus ≥1%) and CD8+ TIL density (0-40% vs. 41-100%) for local control, progression-free (PFS) and overall survival (OS) as well as correlations with clinicopathological features were evaluated. RESULTS:Median OS was 14 months (range: 3-167 months). The OS rates at 1- and 2 years were 68 and 20%. Local control of the entire cohort at 1 and 2 years were 74 and 61%. Median PFS, 1-year and 2-year PFS were 13 ± 1.4 months, 58 and 19%. PD-L1 expression

Published
2020

16. Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center Analysis.

Author

Karin, Monika, Taugner, Julian, Käsmann, Lukas, Eze, Chukwuka, Roengvoraphoj, Olarn, Tufman, Amanda, Belka, Claus, and Manapov, Farkhad

Subjects
NSCLC, multimodal treatment, prognostic factor, stage III, survival, Oncology and Carcinogenesis
Abstract

Inoperable stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous patient cohort. Multimodal treatment approaches including radiotherapy have been the new standard of care, with promising outcomes. The planning target volume (PTV), including the primary tumor, involved lymph node stations and safety margins, can vary widely. In order to evaluate the impact of the PTV for overall survival (OS), progression-free survival (PFS) and loco-regional control, we analyzed retrospective and prospective data of 122 consecutive patients with inoperable stage III NSCLC treated with CRT. The majority of patients (93%) received a total dose ≥ 60 Gy and 92% of all patients were treated with concurrent or sequential chemotherapy. Median follow-up for the entire cohort was 41.2 (range: 3.7-108.4) months; median overall survival (OS) reached 20.9 (95% CI: 14.5-27.3) months. PTVs from 500 to 800 ccm were evaluated for their association with survival in a univariate analysis. In a multivariate analysis including age, gender, total radiation dose and histology, PTV ≥ 700 ccm remained a significant prognosticator of OS (HR: 1.705, 95% CI: 1.071-2.714, p = 0.025). After propensity score matching (PSM) analysis with exact matching for Union internationale contre le cancer (UICC) TNM Classification (7th ed.)T- and N-stage, patients with PTV < 700 ccm reached a median PFS and OS of 11.6 (95% CI: 7.3-15.9) and 34.5 (95% CI: 25.6-43.4) months vs. 6.2 (95% CI: 3.1-9.3) (p = 0.057) and 12.7 (95% CI: 8.5-16.9) (p < 0.001) months in patients with PTV ≥ 700 ccm, respectively. Inoperable stage III NSCLC patients with PTV ≥ 700 ccm had significantly detrimental outcomes after conventionally fractionated CRT. PTV should be considered as a stratification factor in multimodal clinical trials for inoperable stage III NSCLC.

Published
2020

17. Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy

Author

Taugner, Julian, Käsmann, Lukas, Eze, Chukwuka, Dantes, Maurice, Roengvoraphoj, Olarn, Gennen, Kathrin, Karin, Monika, Petruknov, Oleg, Tufman, Amanda, Belka, Claus, and Manapov, Farkhad

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Lung Cancer, Cancer, Clinical Research, Lung, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Non-small cell lung cancer, survival-score, prognostic factors, multimodal therapy, Oncology and carcinogenesis
Abstract

BackgroundStage III non-small cell lung cancer (NSCLC) represents a heterogeneous disease regarding principal patient- and tumor characteristics. A simple score may aid in personalizing multimodal therapy.MethodsThe data of 99 consecutive patients with performance status ECOG 0-1 treated until the end of 2016 with multimodal approach for inoperable NSCLC (UICC 7th edition stage IIIA/B) were evaluated. Patient- and tumor-related factors were examined for their impact on overall survival. Factors showing a negative association with prognosis were then included in the score. Three subgroups with low, intermediate and high-risk score were defined. The results were then validated in the prospective cohort, which includes 45 patients.ResultsMost Patients were treated with concurrent (78%) or sequential (11%) chemoradiotherapy. 53% received induction chemotherapy. Median survival for the entire cohort was 20.8 (range: 15.3-26.3) months. Age (P=0.020), gender (P=0.007), pack years (P=0.015), tumor-associated atelectasis (P=0.004) and histology (P=0.004) had a significant impact on overall survival and were scored with one point each. Twelve, 59 and 28 patients were defined to have a low (0-1 points), intermediate (2-3 points) and high-risk (4-5 points) score. Median survival, 1-, 2- and 3-year survival rates were not reached, 100%, 83% and 67% in the low, 22.9 months, 80%, 47% and 24% intermediate and 13.7 months, 57%, 25% and 18% high-risk patients, respectively (P

Published
2019

18. Corrigendum to “First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations” [Eur J Cancer 199 (2024) 113556]

Author

Blasi, Miriam, primary, Kuon, Jonas, additional, Lüders, Heike, additional, Misch, Daniel, additional, Kauffmann-Guerrero, Diego, additional, Hilbrandt, Moritz, additional, Kazdal, Daniel, additional, Falkenstern-Ge, Roger-Fei, additional, Hackanson, Björn, additional, Dintner, Sebastian, additional, Faehling, Martin, additional, Kirchner, Martina, additional, Volckmar, Anna-Lena, additional, Kopp, Hans-Georg, additional, Allgäuer, Michael, additional, Grohé, Christian, additional, Tufman, Amanda, additional, Reck, Martin, additional, Frost, Nikolaj, additional, Stenzinger, Albrecht, additional, Thomas, Michael, additional, and Christopoulos, Petros, additional

Published
2024
Full Text
View/download PDF

19. Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade

Author

Wyss, Nina, primary, Berner, Fiamma, additional, Walter, Vincent, additional, Jochum, Ann-Kristin, additional, Purde, Mette T., additional, Abdou, Marie-Therese, additional, Sinnberg, Tobias, additional, Hofmeister, Kathrin, additional, Pop, Oltin T, additional, Hasan Ali, Omar, additional, Bauer, Jens, additional, Cheng, Hung-Wei, additional, Lütge, Mechthild, additional, Klümper, Niklas, additional, Diem, Stefan, additional, Kosaloglu-Yalcin, Zeynep, additional, Zhang, Yizheng, additional, Sellmer, Laura, additional, Macek, Boris, additional, Karbach, Julia, additional, König, David, additional, Läubli, Heinz, additional, Zender, Lars, additional, Meyer, Britta S., additional, Driessen, Christoph, additional, Schürch, Christian M., additional, Jochum, Wolfram, additional, Amaral, Teresa, additional, Heinzerling, Lucie, additional, Cozzio, Antonio, additional, Hegazy, Ahmed N., additional, Schneider, Tino, additional, Brutsche, Martin H, additional, Sette, Alessandro, additional, Lenz, Tobias L., additional, Walz, Juliane, additional, Rammensee, Hans-Georg, additional, Früh, Martin, additional, Jäger, Elke, additional, Becher, Burkhard, additional, Tufman, Amanda, additional, Nuñez, Nicolas, additional, Joerger, Markus, additional, and Flatz, Lukas, additional

Published
2024
Full Text
View/download PDF

26. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma

Author

Budczies, Jan, Kirchner, Martina, Kluck, Klaus, Kazdal, Daniel, Glade, Julia, Allgäuer, Michael, Kriegsmann, Mark, Heußel, Claus-Peter, Herth, Felix J., Winter, Hauke, Meister, Michael, Muley, Thomas, Goldmann, Torsten, Fröhling, Stefan, Wermke, Martin, Waller, Cornelius F., Tufman, Amanda, Reck, Martin, Peters, Solange, Schirmacher, Peter, Thomas, Michael, Christopoulos, Petros, and Stenzinger, Albrecht

Published
2022
Full Text
View/download PDF

32. Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment.

Author

Lambrecht, Laura, Arnold, Paola, Behr, Jürgen, Mertsch, Pontus, Tufman, Amanda, and Kauffmann-Guerrero, Diego

Subjects
PATIENT selection, PROGNOSIS, OVERALL survival, GLASGOW Coma Scale, UNIVARIATE analysis
Abstract

Background: Small-cell lung cancer (SCLC) is a highly aggressive tumor, and overall survival (OS) remains poor despite intensive efforts to develop new treatment strategies. In second line, topotecan is the only approved drug, with a median OS of 5.9 months. However, real-world SCLC patients are often in worse condition and harbor more comorbidities than study populations. Therefore, the real-world performance of topotecan may differ from that seen in studies. Here, we analyzed outcomes of SCLC patients receiving topotecan and identified predictive and prognostic markers. Patients and Methods: We retrospectively analyzed 44 consecutive SCLC patients receiving topotecan between 2015 and 2022. We analyzed baseline characteristics (age, ECOG-PS, topotecan cycles, and dosage) and pre-treatment blood values (LDH, CRP, sodium) as well as prognostic scores (neutrophil/lymphocyte ratio (NLR), thrombocyte/lymphocyte ratio (TLR), Glasgow Prognostic Score, prognostic nutritional score, systemic inflammation index (SII), and the prognostic index) extracted from electronic patients' charts to identify predictive and prognostic markers. Results: In our cohort, mPFS and mOS were only 1.9 and 5.6 months, respectively. Gender, ECOG-PS, active brain metastases, NLR, GPS, PNI, and SII significantly influenced PFS and OS in univariate analysis. ECOG-PS (p > 0.001), active brain metastases (p = 0.001), and SII (p = 0.008) were significant independent prognostic variables in a multivariate COX regression model. Selecting patients by these three markers achieved an mPFS of 5.7 months and thus increased the mPFS three-fold. Patients not meeting all criteria had an mPFS of 1.8 months (p = 0.006). Patients identified by prognostic markers had an mOS of 9.1 months (p = 0.002). Conclusions: The efficacy of topotecan in SCLC real-world patients is poor, indicating that many patients were treated without any benefit. Easy-to-obtain markers can predict response and treatment efficacy and should therefore be validated in larger cohorts to identify patients who are more likely to benefit from topotecan. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Herausgeber

Author

Endres, Stefan, primary, Dechant, Claudia, additional, Drey, Michael, additional, Hoffmann, Ulrich, additional, Kahnert, Kathrin, additional, Kauffmann-Guerrero, Diego, additional, Klauss, Volker, additional, König, Andreas, additional, Mertsch, Pontus, additional, Nährig, Susanne, additional, Nowak, Dennis, additional, Ochmann, Uta, additional, Oduncu, Fuat S., additional, Röpcke, Felix, additional, Rupprecht, Harald, additional, Schewe, Stefan, additional, Schmidmaier, Ralf, additional, Steiner, Florian, additional, Syunyaeva, Zulfiya, additional, Tatò, Federico, additional, Tufman, Amanda, additional, and Völkl, Andreas, additional

Published
2022
Full Text
View/download PDF

36. Pneumologie

Author

Kahnert, Kathrin, primary, Kauffmann-Guerrero, Diego, additional, Mertsch, Pontus, additional, Nährig, Susanne, additional, Nowak, Dennis, additional, Ochmann, Uta, additional, Steiner, Florian, additional, Syunyaeva, Zulfiya, additional, and Tufman, Amanda, additional

Published
2022
Full Text
View/download PDF

38. Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)

Author

Tufman, Amanda, Neumann, Jens, Manapov, Farkhad, Sellmer, Laura, Jung, Andreas, Kauffmann-Guerrero, Diego, Kahnert, Kathrin, Mertsch, Pontus, Borgmeier, Astrid, Semrau, Sabine, Rittmeyer, Achim, Ulm, Bernhard, Ulm, Kurt, Flentje, Michael, Fietkau, Rainer, and Huber, Rudolf Maria

Published
2021
Full Text
View/download PDF

41. Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)

Author

Peters, Solange, Felip, Enriqueta, Dafni, Urania, Tufman, Amanda, Guckenberger, Matthias, Álvarez, Ruth, Nadal, Ernest, Becker, Annemarie, Vees, Hansjörg, Pless, Miklos, Martinez-Marti, Alex, Lambrecht, Maarten, Andratschke, Nicolaus, Tsourti, Zoi, Piguet, Anne-Christine, Roschitzki-Voser, Heidi, Gasca-Ruchti, Adrian, Vansteenkiste, Johan, Stahel, Rolf A., and De Ruysscher, Dirk

Published
2021
Full Text
View/download PDF

43. Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 with Focus on Perioperative Therapy, Radiotherapy, and Bispecific T-Cell Engagers.

Author

Kemper, Marcel, Soltani Germy, Puyan, Acker, Fabian, Luan, Jingting, Griesinger, Frank, Tufman, Amanda, Kropf-Sanchen, Cornelia, Overbeck, Tobias Raphael, Bleckmann, Annalen, and Blasi, Miriam

Subjects
MEDICAL societies, T cells, SMALL cell lung cancer, ONCOLOGY
Abstract

This document summarizes the key findings and insights from the 2023 European Society for Medical Oncology (ESMO) annual meeting, with a focus on thoracic oncology. It covers various topics such as immunotherapy-based therapy in nonmetastatic settings, radiotherapy in non-small cell lung cancer (NSCLC), and bispecific T-cell engagers in small cell lung cancer (SCLC). The report includes data from clinical trials and studies, highlighting the effectiveness and safety of different treatment approaches. It also mentions the approval of certain therapies by regulatory bodies and emphasizes the need for further research in specific patient subgroups. Authored by a team of experts, this report provides valuable insights and perspectives for library patrons conducting research in this field. [Extracted from the article]

Published
2024
Full Text
View/download PDF

44. The Association between the Body Mass Index, Chronic Obstructive Pulmonary Disease and SUV of the Non-Tumorous Lung in the Pretreatment [ 18 F]FDG-PET/CT of Patients with Lung Cancer.

Author

Wehlte, Lukas, Walter, Julia, Daisenberger, Lea, Kuhnle, Felix, Ingenerf, Maria, Schmid-Tannwald, Christine, Brendel, Matthias, Kauffmann-Guerrero, Diego, Heinzerling, Lucie, Tufman, Amanda, Pfluger, Thomas, and Völter, Friederike

Subjects
CHRONIC obstructive pulmonary disease, BODY mass index, LUNG cancer, CANCER patients, LUNGS
Abstract

Background: A debate persists on the prognostic value of the pre-therapeutic standardized uptake value (SUV) of non-tumorous lung tissue for the risk assessment of therapy-related pneumonitis, with most studies lacking significant correlation. However, the influence of patient comorbidities on the pre-therapeutic lung SUV has not yet been systematically evaluated. Thus, we aimed to elucidate the association between comorbidities, biological variables and lung SUVs in pre-therapeutic [18F]FDG-PET/CT. Methods: In this retrospective study, the pre-therapeutic SUV in [18F]FDG-PET/CT was measured in non-tumorous areas of both lobes of the lung. SUVMEAN, SUVMAX and SUV95 were compared to a multitude of patient characteristics and comorbidities with Spearman's correlation analysis, followed by a Bonferroni correction and multilinear regression. Results: In total, 240 patients with lung cancer were analyzed. An elevated BMI was significantly associated with increased SUVMAX (β = 0.037, p < 0.001), SUVMEAN (β = 0.017, p < 0.001) and SUV95 (β = 0.028, p < 0.001). Patients with chronic obstructive pulmonary disease (COPD) showed a significantly decreased SUVMAX (β = −0.156, p = 0.001), SUVMEAN (β = −0.107, p < 0.001) and SUV95 (β = −0.134, p < 0.001). Multiple other comorbidities did not show a significant correlation with the SUV of the non-tumorous lung. Conclusions: Failure to consider the influence of BMI and COPD on the pre-therapeutic SUV measurements may lead to an erroneous interpretation of the pre-therapeutic SUV and subsequent treatment decisions in patients with lung cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms

Author

Schütte, Wolfgang, additional, Gütz, Sylvia, additional, Nehls, Wiebke, additional, Blum, Torsten Gerriet, additional, Brückl, Wolfgang, additional, Buttmann-Schweiger, Nina, additional, Büttner, Reinhard, additional, Christopoulos, Petros, additional, Delis, Sandra, additional, Deppermann, Karl M., additional, Dickgreber, Nikolas, additional, Eberhardt, Wilfried, additional, Eggeling, Stephan, additional, Fleckenstein, Jochen, additional, Flentje, Michael, additional, Frost, Nikolaj, additional, Griesinger, Frank, additional, Grohé, Christian, additional, Gröschel, Andreas, additional, Guckenberger, Matthias, additional, Hecker, Erich, additional, Hoffmann, Hans, additional, Huber, Rudolf M., additional, Junker, Klaus, additional, Kauczor, Hans-Ulrich, additional, Kollmeier, Jens, additional, Kraywinkel, Klaus, additional, Krüger, Marcus, additional, Kugler, Christian, additional, Möller, Miriam, additional, Nestle, Ursula, additional, Passlick, Bernward, additional, Pfannschmidt, Joachim, additional, Reck, Martin, additional, Reinmuth, Niels, additional, Rübe, Christian, additional, Scheubel, Robert, additional, Schumann, Christian, additional, Sebastian, Martin, additional, Serke, Monika, additional, Stoelben, Erich, additional, Stuschke, Martin, additional, Thomas, Michael, additional, Tufman, Amanda, additional, Vordermark, Dirk, additional, Waller, Cornelius, additional, Wolf, Jürgen, additional, Wolf, Martin, additional, and Wormanns, Dag, additional

Published
2023
Full Text
View/download PDF

47. Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer

Author

Salazar, Ylia, Zheng, Xiang, Brunn, David, Raifer, Hartmann, Picard, Felix, Zhang, Yajuan, Winter, Hauke, Guenther, Stefan, Weigert, Andreas, Weigmann, Benno, Dumoutier, Laure, Renauld, Jean-Christophe, Waisman, Ari, Schmall, Anja, Tufman, Amanda, Fink, Ludger, Brune, Bernhard, Bopp, Tobias, Grimminger, Friedrich, Seeger, Werner, Pullamsetti, Soni Savai, Huber, Magdalena, and Savai, Rajkumar

Subjects
Lung cancer -- Development and progression, B cells, Cancer research, Stem cells, Cancer metastasis -- Development and progression, Health care industry
Abstract

Immune microenvironment plays a critical role in lung cancer control versus progression and metastasis. In this investigation, we explored the effect of tumor-infiltrating lymphocyte subpopulations on lung cancer biology by studying in vitro cocultures, in vivo mouse models, and human lung cancer tissue. Lymphocyte conditioned media (CM) induced epithelial-mesenchymal transition (EMT) and migration in both primary human lung cancer cells and cell lines. Correspondingly, major accumulation of Th9 and Th17 cells was detected in human lung cancer tissue and correlated with poor survival. Coculturing lung cancer cells with Th9/Th17 cells or exposing them to the respective CM induced EMT in cancer cells and modulated the expression profile of genes implicated in EMT and metastasis. These features were reproduced by the signatory cytokines IL-9 and IL-17, with gene regulatory profiles evoked by these cytokines partly overlapping and partly complementary. Coinjection of Th9/Th17 cells with tumor cells in WT, [Rag1.sup.-/-], [Il9r.sup.-/-], and [Ilra.sup.-/-] mice altered tumor growth and metastasis. Accordingly, inhibition of IL-9 or IL-17 cytokines by neutralizing antibodies decreased EMT and slowed lung cancer progression and metastasis. In conclusion, Th9 and Th17 lymphocytes induce lung cancer cell EMT, thereby promoting migration and metastatic spreading and offering potentially novel therapeutic strategies., Introduction Lung cancer is the leading cause of cancer mortality worldwide, accounting for up to 19% of all cancer-related deaths. Numbers of deaths due to lung cancer are even greater [...]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results